Pharmaceutical intermediates
Belzutifan Intermediates
3 pharmaceutical intermediates for Belzutifan. Indication: Hippel-Lindau syndrome; renal cell carcinoma; hemangioblastoma; pancreatic neuroendocrine tumor; central nervous system tumor; neuroblastoma.
About Belzutifan
- Originator
- Peloton Therapeutics Inc
- Indication
- Hippel-Lindau syndrome; renal cell carcinoma; hemangioblastoma; pancreatic neuroendocrine tumor; central nervous system tumor; neuroblastoma
- Approved Date
- 08/13/2021
- NCE Patent
- 08/13/2026
- DS/DP
- 09/05/2034
Available intermediates
3 intermediates currently listed for Belzutifan. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 3-fluoro-5-((7-(methylsulfonyl)-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)benzonitrile | 1672665-55-2 | / | / |
| (R)-3-Fluoro-5-((3-hydroxy-7-(methylsulfonyl)-1-oxo-2,3-dihydro-1H-inden-4-yl)oxy)benzonitrile | 2738675-96-0 | / | / |
| Fluoro-2,3-dihydro-7-(methylsulfonyl)-1H-inden-1-one | 1672665-29-0 | / | / |
Building toward Belzutifan?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →